Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 218

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 218
---
 contains reports, proxy and information statements, and other information
regarding issuers, including us, that file electronically with the SEC. Our filings with the SEC are available to the public through the
SEC’s website athttp://www.sec.gov. Our corporate website is located at www.biodexapharma.com. Information contained
on our website is not part of, or incorporated in, this prospectus.

We have three wholly owned
subsidiaries, as well as several indirectly owned subsidiaries and joint ventures. The following table sets forth a description of the
Group.

| Subsidiaries                                | Country of Incorporation | Voting Interest |
| Subsidiaries of Biodexa Pharmaceuticals PLC |                          |                 |
| Biodexa Pharmaceuticals (Wales) Limited     | England and Wales        | 100%            |
| Biodexa Ltd                                 | England and Wales        | 100%            |
| Haaland UK Limited (1)                      | England and Wales        | 100%            |
| Subsidiaries of Biodexa Ltd                 |                          |                 |
| Pharmida AG (1)                             | Switzerland              | 100%            |

_______________

| (1) | Dormant entities. |

| 107 |

Capital Expenditures

Our capital expenditures amounted
to £Nil and £4,000 for the six months ended for the six months ended June 30, 2024 and 2023, and £0.03 million and £0.06
million for the years ended December 31, 2023 and 2022.

For the six months ended June
30, 2023, our principal capital expenditures related to laboratory equipment.

For the years ended December
31, 2023 and December 31, 2022, our principal capital expenditures largely related to investment in laboratory equipment.

| 108 |

<div align='center'>MANAGEMENT</div>

Directors and Senior Management

The following table sets forth
certain information about our current directors and senior management. The professional address of each of the directors and officers
is care of Biodexa Pharmaceuticals PLC, Caspian Point, 1 Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

| Name (1)                             |     |     Age at 
 12/31/2024 |     | Position/Title                                                |
| Stephen Stamp                        |     |         63 |     | Chief Executive Officer and Chief Financial Officer